Tumor angiogenesis leads to abnormal vessel formation that promotes immune evasion, and it has been recently demonstrated that the combination of anti-PD-1/PD-L1 based immunotherapy and antiangiogenic treatment by using (VEGFR-2) inhibitors results in intra-tumor immune modulation and enhances the anti-tumor efficacy of PD-1/PD-L1 blockade [6]. This evidence concerns the gene KDR and neoplasm.